REC Share Price

Open 29.47 Change Price %
High 29.69 1 Day 0.16 0.54
Low 29.32 1 Week 0.66 2.29
Close 29.53 1 Month 2.27 8.33
Volume 245971 1 Year 8.58 40.95
52 Week High 29.74
52 Week Low 20.94
REC Important Levels
Resistance 2 29.87
Resistance 1 29.73
Pivot 29.51
Support 1 29.33
Support 2 29.19
BIT Italy Most Active Stocks
SPM 0.42 -6.67%
SPM 0.42 -6.67%
ISP 2.07 -2.36%
PMI 0.36 0.00%
PMI 0.36 0.00%
TIT 0.76 -1.30%
ENEL 4.02 1.26%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
EEMS 0.14 16.67%
TAS 4.07 12.74%
TAS 4.07 12.74%
TAS 4.07 12.74%
POPR 0.32 6.67%
VRW 1.13 6.60%
More..
BIT Italy Top Losers Stocks
PRS 0.09 -10.00%
PRS 0.09 -10.00%
PRS 0.09 -10.00%
PRS 0.09 -10.00%
SPMR 5.41 -9.83%
MCH 0.67 -6.94%
MCH 0.67 -6.94%
MCH 0.67 -6.94%
SPM 0.42 -6.67%
SPM 0.42 -6.67%
More..

Recordati (BIT: REC)

REC Technical Analysis 5
As on 24th Feb 2017 REC Share Price closed @ 29.53 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 26.43 & Strong Buy for SHORT-TERM with Stoploss of 27.30 we also expect STOCK to react on Following IMPORTANT LEVELS.
REC Target for February
1st Target up-side 27.34
2nd Target up-side 28
3rd Target up-side 28.67
1st Target down-side 25.44
2nd Target down-side 24.78
3rd Target down-side 24.11
REC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.recordati.com
REC Address
REC
Via Matteo Civitali 1
Milano, MI 20148
Italy
Phone: 39 02 487871
Fax: 39 02 40 07 37 47
Interactive Technical Analysis Chart Recordati ( REC BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Recordati
REC Business Profile
Recordati S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals. It offers pharmaceuticals in various therapeutic areas, including antibiotics and antivirals, cardiovascular, central nervous system, dermatological, gastroenterology, genito-urinary system, muscolo-skeletal disorders and pain therapy, and obstetics and gynaecology; and non-prescription pharmaceuticals. The company’s flagship product is ZANIDIP (lercanidipine), a calcium-channel blocker for the treatment of hypertension. Its products also include Zanipress/Zanitek, a combination of lercanidipine and enalapril for the treatment of hypertension; Carbaglu, which is approved in the European Union and is under Phase III clinical trials in the United States for the treatment of organic acidemias; REC 0482 for the treatment of benign prostatic hyperplasia, which is under Phase III clinical trials; and Lercanidipine/enalapril fixed combination, which is in pre-registration stage for the treatment of essential hypertension. In addition, it offers gastroenterological drugs, oral rehydration products, probiotics, and OTC brands for gynecological use. Its products under Phase II clinical trials include Cystadrops for the treatment of ocular cystinosis, and REC 0422 to treat overactive bladder and incontinence; and Phase I clinical trials comprise REC 1819 for the treatment of overactive bladder and incontinence, and REC 0438 to treat overactive bladder in patients with spinal lesions. Further, the company produces pharmaceutical chemicals, such as active ingredients and intermediates for the generic drugs market. Recordati S.p.A has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati S.p.A. is a subsidiary of Fimei S.p.A.